Discover the Global PharmaPoint: Prophylactic Human Papillomavirus Vaccines US Drug Forecast and Market Analysis to 2022 "The Report PharmaPoint: Prophylactic Human Papillomavirus Vaccines US Drug Forecast and Market Analysis to 2022 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. MarketResearchReports.biz" The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Mercks Gardasil, with GlaxoSmithKlines (GSKs) HPV vaccine Cervarix providing the only competition. The introduction of Mercks ninevalent vaccine (V503) is set to change the future landscape of the HPV vaccines sector. In the US the total number of HPV vaccine doses delivered annually is likely to grow steadily over the next few years, as more males receive vaccination and Mercks ninevalent vaccine V503 becomes available in 2015. US market growth will contribute to global growth in the HPV vaccines sector. There is no indication that coverage rates for adolescent girls will increase dramatically over the forecast period, as they have been relatively stable over the past few years. However, a modest increase will likely be achieved following the introduction of V503, which will be accompanied by a marketing and awareness campaign. View Report At :http://www.marketresearchreports.biz/analysis/210570 Scope Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in the US from 20122022. Analysis of the impact of key events as well the drivers and restraints affecting the US Prophylactic Human Papillomavirus Vaccines disease market.
Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and indepth analysis of drug performance Obtain sales forecast for drugs from 20122022 in the US Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/210570 Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 2.1 Catalyst 9 2.2 Related Reports 9 2.3 Upcoming Related Reports 11 3 Disease Overview 12 3.1 Etiology and Pathophysiology 12 3.1.1 Etiology 12 3.1.2 Pathophysiology 13 3.2 Symptoms 15 4 Vaccination Recommendations and Coverage Rates 17 4.1 US 17 4.1.1 Vaccination Recommendations and Policies 17 4.1.2 Vaccination Coverage 17 4.1.3 Clinical Practice 19 5 Competitive Assessment 21 5.1 Overview 21 5.2 Strategic Competitor Assessment 21 5.3 Product Profiles 23 5.3.1 Gardasil 23 5.3.2 Cervarix 29 6 Unmet Need and Opportunity 34 6.1 Overview 34 6.2 Protection against Multiple HPV Types 35 6.2.1 Unmet Need 35 6.2.2 Gap Analysis 36 6.2.3 Opportunity 37 6.3 Vaccine Coverage Rates 37 6.3.1 Unmet Need 37 6.3.2 Gap Analysis 38
6.3.3 Opportunity 38 6.4 Perception of Vaccine Safety 39 6.4.1 Unmet Need 39 6.4.2 Gap Analysis 40 6.4.3 Opportunity 40 6.5 Awareness of HPV Vaccination 41 6.5.1 Unmet Need 41 6.5.2 Gap Analysis 41 6.5.3 Opportunity 42 6.6 Affordability of HPV Vaccines 42 6.6.1 Unmet Need 42 6.6.2 Gap Analysis 43 6.6.3 Opportunity 43 6.7 Coverage of HPV Types Prevalent in Certain Populations 44 6.7.1 Unmet Need 44 About us MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Contact Mr. Nachiket State Tower 90 Sate Street, Suite 700 Albany, NY 12207 Tel: +15186212074 Website: http://www.marketresearchreports.biz/ E: sales@marketresearchreports.biz